SCHEMBL5876607

SCHEMBL5876607

COc1ccc(C2(c3ccc(OC)cc3)C=Cc3c(C#N)n[nH]c3C2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.34
ALDH1A1 P00352 7/20 0.33
HTT P42858 3/20 0.33
LMNA P02545 3/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 4/20 0.32
RAB9A P51151 4/20 0.32
HSD17B10 Q99714 3/20 0.32
HPGD P15428 3/20 0.32
KDM4E B2RXH2 3/20 0.32
NPC1 O15118 3/20 0.32
GAA P10253 2/20 0.32
TSHR P16473 1/20 0.32
USP8 P40818 1/20 0.32
MGAT2 Q10469 2/20 0.31
CUL4A Q13619 2/20 0.31
MEN1 O00255 1/20 0.31
MAPK10 P53779 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5877439 0.95 OPRM1 (0.36) ALPLALDH1A1LMNAPOLBMAPT
SCHEMBL5876734 0.86 SHMT1 (0.39) HTTMAPTRAB9ANPC1GAA
SCHEMBL5877119 0.86 SHMT1 (0.38) HTTLMNAMAPTRAB9AHPGD
SCHEMBL5876861 0.84 ERBB2 (0.35)
SCHEMBL6616435 0.83 NPC1 (0.34) ALDH1A1RAB9AHPGDKDM4ENPC1
SCHEMBL5877129 0.83 ERBB2 (0.33)
SCHEMBL5878239 0.83 ALDH1A1 (0.31) ALDH1A1MAPTMGAT2
SCHEMBL5876406 0.82 ALDH1A1 (0.35) ALDH1A1HTTLMNAMAPTRAB9A
SCHEMBL5878258 0.82
SCHEMBL5878004 0.81 GAA (0.37) ALPLALDH1A1HTTMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT ALPL 3163/4885ALDH1A1 166/4885HTT 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.